ES2537054T3 - Radioprotectores - Google Patents
Radioprotectores Download PDFInfo
- Publication number
- ES2537054T3 ES2537054T3 ES09000547.1T ES09000547T ES2537054T3 ES 2537054 T3 ES2537054 T3 ES 2537054T3 ES 09000547 T ES09000547 T ES 09000547T ES 2537054 T3 ES2537054 T3 ES 2537054T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- hoechst
- cells
- radiation
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN449295 | 1995-07-28 | ||
| AUPN4492A AUPN449295A0 (en) | 1995-07-28 | 1995-07-28 | Radioprotectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2537054T3 true ES2537054T3 (es) | 2015-06-02 |
Family
ID=3788827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09000547.1T Expired - Lifetime ES2537054T3 (es) | 1995-07-28 | 1996-07-26 | Radioprotectores |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6194414B1 (2) |
| EP (2) | EP0857067A4 (2) |
| JP (1) | JP4125369B2 (2) |
| AU (2) | AUPN449295A0 (2) |
| CA (1) | CA2228044C (2) |
| DK (1) | DK2044938T3 (2) |
| ES (1) | ES2537054T3 (2) |
| PT (1) | PT2044938E (2) |
| WO (1) | WO1997004776A1 (2) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996006831A1 (en) * | 1994-08-26 | 1996-03-07 | Auckland Division Cancer Society Of New Zealand Inc. | Novel dna-targeted alkylating agents |
| AU2002367060A1 (en) * | 2001-12-21 | 2003-07-30 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
| CA2518830A1 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| CA2519475A1 (en) | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin cgrp receptor antagonists |
| US8097238B2 (en) * | 2004-02-27 | 2012-01-17 | Peter Maccallum Cancer Institute | Cell targeting conjugates |
| RU2007101544A (ru) * | 2004-06-17 | 2008-08-10 | Уайт (Us) | Антагонисты рецепторов высвобождающего гонадотропин гормона |
| RU2007101509A (ru) * | 2004-06-17 | 2008-07-27 | Уайт (Us) | Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин |
| JP5149620B2 (ja) | 2004-07-23 | 2013-02-20 | エンドサイト，インコーポレイテッド | ２価リンカーおよびその結合体 |
| WO2006031491A2 (en) * | 2004-09-09 | 2006-03-23 | Merck & Co., Inc. | Tricyclic anilide spirolactam cgrp receptor antagonists |
| CN101048383A (zh) * | 2004-11-23 | 2007-10-03 | 惠氏公司 | 促性腺激素释放激素受体拮抗剂 |
| US7582634B2 (en) * | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) * | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) * | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| DE102005019549A1 (de) * | 2005-04-25 | 2006-12-14 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Diaminobenzimidazol |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) * | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1910385B1 (en) | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2008073451A2 (en) * | 2006-12-11 | 2008-06-19 | Sirtris Pharmaceuticals, Inc. | Benzoimidazole derivatives as sirtuin (sir) modulating compounds |
| AU2007335185B2 (en) | 2006-12-21 | 2013-06-27 | Peter Maccallum Cancer Institute | Radioprotector compounds and related methods |
| CN104127878A (zh) | 2007-03-14 | 2014-11-05 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| EP2376502B1 (en) | 2008-12-19 | 2015-06-17 | GlaxoSmithKline LLC | Thiazolopyridine sirtuin modulating compounds |
| CN102933557B (zh) * | 2010-04-06 | 2016-08-03 | 彼得·麦卡勒姆癌症研究所 | 辐射防护剂化合物及方法 |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| EP2908818A4 (en) | 2012-10-16 | 2016-07-13 | Endocyte Inc | CONJUGATES OF DRUG DELIVERY CONTAINING ARTIFICIAL AMINO ACIDS AND METHODS OF USE |
| JP6676650B2 (ja) * | 2015-03-13 | 2020-04-08 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 疾患を処置するためのコンジュゲート |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| RU205631U1 (ru) * | 2021-01-11 | 2021-07-23 | Общество с ограниченной ответственностью "Газпром добыча Уренгой" | Устройство для поверки и калибровки средств измерений малого давления |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670684A1 (de) | 1966-04-01 | 1970-12-03 | Hoechst Ag | Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten |
| WO1990012321A1 (en) | 1989-03-31 | 1990-10-18 | The Cancer Institute Board | Halogenated dna ligand radiosensitisers for cancer therapy |
| US5641764A (en) * | 1989-03-31 | 1997-06-24 | Peter Maccallum Institute | Halogenated DNA ligand radiosensitizers for cancer therapy |
-
1995
- 1995-07-28 AU AUPN4492A patent/AUPN449295A0/en not_active Abandoned
-
1996
- 1996-07-26 JP JP50700597A patent/JP4125369B2/ja not_active Expired - Lifetime
- 1996-07-26 CA CA002228044A patent/CA2228044C/en not_active Expired - Lifetime
- 1996-07-26 EP EP96924709A patent/EP0857067A4/en not_active Withdrawn
- 1996-07-26 DK DK09000547.1T patent/DK2044938T3/en active
- 1996-07-26 ES ES09000547.1T patent/ES2537054T3/es not_active Expired - Lifetime
- 1996-07-26 AU AU65096/96A patent/AU717249B2/en not_active Expired
- 1996-07-26 EP EP09000547.1A patent/EP2044938B1/en not_active Expired - Lifetime
- 1996-07-26 WO PCT/AU1996/000467 patent/WO1997004776A1/en not_active Ceased
- 1996-07-26 US US09/000,313 patent/US6194414B1/en not_active Expired - Lifetime
- 1996-07-26 PT PT90005471T patent/PT2044938E/pt unknown
-
2000
- 2000-08-14 US US09/637,903 patent/US6548505B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU6509696A (en) | 1997-02-26 |
| DK2044938T3 (en) | 2015-05-26 |
| JP2000501697A (ja) | 2000-02-15 |
| EP0857067A4 (en) | 2005-01-19 |
| EP2044938A3 (en) | 2009-07-15 |
| WO1997004776A1 (en) | 1997-02-13 |
| US6194414B1 (en) | 2001-02-27 |
| PT2044938E (pt) | 2015-06-09 |
| EP0857067A1 (en) | 1998-08-12 |
| AUPN449295A0 (en) | 1995-08-24 |
| US6548505B1 (en) | 2003-04-15 |
| CA2228044A1 (en) | 1997-02-13 |
| EP2044938B1 (en) | 2015-02-18 |
| AU717249B2 (en) | 2000-03-23 |
| CA2228044C (en) | 2006-11-28 |
| JP4125369B2 (ja) | 2008-07-30 |
| EP2044938A2 (en) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2537054T3 (es) | Radioprotectores | |
| CN102933557B (zh) | 辐射防护剂化合物及方法 | |
| KR102746242B1 (ko) | Ｒｓｋ 억제제로서 유용한 카르복사미드 유도체 | |
| JP2017160216A (ja) | Ｐａｒｐインヒビターとの組合せ療法 | |
| CN113811333A (zh) | 靶向抗癌核激素受体的化合物 | |
| ES2550589T3 (es) | Compuestos radioprotectores y métodos relacionados | |
| CA3030907A1 (en) | Chelated psma inhibitors | |
| CN102821605A (zh) | 改进的稳定的（e）-4-羧基苯乙烯基-4-氯苄基砜水性制剂 | |
| JPWO2019244954A1 (ja) | ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤 | |
| CN119698299A (zh) | 通过放疗的n-氧化物的前药活化 | |
| CN114478524A (zh) | 1,8-萘啶类化合物及其应用 | |
| CA3102434A1 (en) | Selective a2a receptor antagonist | |
| CN111499623B (zh) | 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途 | |
| WO2024030529A1 (en) | Prodrugs of myc inhibitors | |
| WO2025132724A1 (en) | Azo(hetero)aryl derivatives for use as radioswitchs and their use in therapy | |
| HK40123451A (zh) | 双杂环取代的卟啉衍生物、其制备方法及其作为光敏剂的用途 | |
| CN117982636A (zh) | 一种预防和/或治疗脑胶质瘤的联合用药组合产品以及联合制药用途 |